查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1916934

噬菌體療法試劑盒市場：按試劑盒類型、給藥方法、產品類型、應用和最終用戶分類－全球預測（2026-2032 年）

Phage Therapy Kits Market by Kit Type, Delivery Method, Product Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年噬菌體療法試劑盒市值為 4.2813 億美元，預計到 2026 年將成長至 5.2092 億美元，年複合成長率為 21.73%，到 2032 年將達到 16.9624 億美元。

主要市場統計數據
基準年 2025 4.2813億美元
預計年份：2026年 5.2092億美元
預測年份：2032年 1,696,240,000 美元
複合年成長率 (%) 21.73%

噬菌體療法試劑盒的整合實施：重點介紹標準化試劑和工作流程如何促進研究、臨床和工業領域的轉化科學

噬菌體療法試劑盒正與微生物學、基因組學和臨床實踐的進步相融合，形成一套快速成熟的工具，用於輔助發現、診斷和治療應用開發。這些試劑盒整合了試劑、對照品和通訊協定，可在研究、臨床和工業環境中實現噬菌體的可重複分離、純化、定量和定序。隨著科學界和監管相關人員探索傳統抗菌藥物的替代方案，基於噬菌體的方法正從學術研究走向實際應用，這需要使用標準化的高品質試劑盒來確保結果的一致性。

快速的技術創新、臨床領域日益成長的興趣以及跨產業的應用，正在將噬菌體療法試劑盒領域重塑為一個更標準化和可擴展的生態系統。

噬菌體療法試劑盒市場正經歷著變革性的轉變，這主要得益於技術的成熟、臨床需求的成長以及跨領域的應用。定序技術和高效能檢測方法的進步提高了噬菌體鑑定的準確性和速度，而純化和定量試劑的改進則降低了實驗室間的差異。因此，供應商正致力於創新，提供承包解決方案，降低非專業實驗室的進入門檻，並加速研發和產品開發的迭代週期。

評估近期關稅對實驗室耗材和試劑盒採購、供應鏈策略以及供應商選擇的商業性影響。

2025年實施的關稅政策調整為噬菌體療法試劑盒的生產商、分銷商和採購商帶來了新的考量。某些實驗室耗材和試劑關稅的提高增加了依賴跨境供應鏈的企業的到岸成本，促使採購團隊重新評估籌資策略和總到岸成本。為此，許多生產商和經銷商正在探索近岸外包、雙重採購和策略性庫存佈局等策略，以降低關稅波動帶來的風險，並確保關鍵組件（例如專用緩衝液和對照品）的持續供應。

全面的細分分析揭示了應用領域、套件類型、最終用戶、交付方式和產品類型如何相互交織，從而塑造未滿足的需求和供應商差異化。

在評估噬菌體療法試劑盒的產品定位、研發重點領域和商業化部署時，了解市場區隔至關重要。按應用領域分類，需求主要來自農業領域，重點關注作物和牲畜病原體控制；食品安全項目，尋求可靠的病原體檢測和檢驗；研究活動涵蓋基礎研究到商業研發；以及針對感染疾病、腫瘤應用和傷口護理干預的治療開發管道。在研究領域，基礎研究優先考慮平台的多功能性和發現試劑，而商業性研發則強調可重複性和監管文件。治療應用進一步細分為傳染病領域，例如胃腸道感染疾病和院內感染疾病，以及將噬菌體生物學與輔助性治療相結合的腫瘤和傷口護理專案。

區域戰略趨勢和業務要務表明，美洲、歐洲、中東和非洲以及亞太地區需要差異化的產品、監管和分銷方法。

區域趨勢將對噬菌體療法試劑盒的推廣管道、監管預期和商業策略產生重大影響。在美洲，強大的生物技術創新中心、廣泛的臨床試驗活動以及對替代抗菌藥物較為開放的法規環境，為研究驅動型和轉化型試劑盒的推廣應用創造了有利條件。該地區還需要可擴展的供應鏈和強力的售後支持，以服務包括學術機構、臨床機構和商業終端用戶在內的多元化用戶層。

主要企業層面深入洞察產品檢驗、品質系統和策略夥伴關係關係如何創造競爭優勢並影響臨床和研究買家的採納情況。

噬菌體療法試劑盒的競爭格局呈現出多元化的特點，包括專業試劑生產商、拓展噬菌體相關工作流程的成熟儀器製造商，以及提供小眾高性能解決方案的專業供應商。主要企業憑藉其深厚的技術檢驗、提供臨床和研究級文件的能力，以及支援上下游工作流程的廣泛產品生態系統脫穎而出。此外，那些投資於完善的品管系統、批次級可追溯性和清晰使用說明的企業，更有利於被診斷中心和生物製藥開發公司採用。

為產業領導者提供切實可行的建議，以加強檢驗、實現供應鏈多元化並提高客戶參與，從而推動噬菌體療法試劑盒的持續普及應用。

為了抓住噬菌體試劑盒生態系統中的機遇，產業領導者應優先採取措施，增強技術可靠性、供應鏈韌性和客戶參與。首先，投資於完善的檢驗包裝，包括臨床和研究級別的文件、批間性能數據以及第三方對比測試。這些材料將降低受監管終端用戶的採用門檻，並加速其融入轉換工作流程。其次，實現生產和分銷地點的多元化，以降低關稅風險和海關延誤，並制定替代採購方案，以確保關鍵試劑的持續供應。

本文介紹了依證的調查方法，該方法結合了相關人員訪談、文獻綜述和分析框架，以確保研究結果具有可操作性和檢驗。

本報告整合了第一手和第二手調查方法，以確保分析的嚴謹性和對實踐者的實用性。第一手研究包括對生物製藥研發部門、診斷實驗室、醫院採購團隊、學術研究團隊和農業科學領域的相關人員進行結構化訪談。這些訪談重點在於影響試劑盒選擇和使用的技術要求、檢驗預期、採購行為和物流限制。此外，與生產和分銷專家的討論也提供了關於供應鏈韌性、品質保證實踐和監管文件需求的實用觀點。

本文全面探討了噬菌體療法試劑盒不斷變化的作用，以及企業應利用哪些策略槓桿來推動其在研究、臨床和應用領域的成功應用。

總之，噬菌體療法試劑盒作為一種平台技術，在科研創新、臨床應用和病原體控制的交叉領域中發揮著至關重要的作用。定序、純化和定量技術的進步降低了技術門檻，拓寬了噬菌體工具的可靠應用範圍。同時，關稅變化、複雜的供應鏈和各地區不同的監管要求等商業性現實，要求生產商和採購商都應做出深思熟慮的策略性回應。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 噬菌體療法試劑盒市場（按試劑盒類型分類）

  • 完整套裝
  • 消耗品
  • 試劑組
    • 控制
      • 陰性對照
      • 陽性對照
    • 裂解緩衝液
    • 染色試劑

9. 依給藥途徑分類的噬菌體療法試劑盒市場

  • 注射
    • 肌肉內注射
    • 靜脈注射
    • 皮下注射
  • 口服
  • 外用

第10章 噬菌體療法試劑盒市場（依產品類型分類）

  • 診斷試劑盒
  • 淨化套裝
  • 定量試劑盒
    • 斑塊檢測試劑盒
    • qPCR試劑盒
      • 探針底座套件
      • SYBR 綠色套件
  • 定序試劑盒

第11章 噬菌體療法試劑盒市場依應用領域分類

  • 農業
  • 食品安全
  • 研究
    • 基礎研究
    • 商業研發
  • 治療
    • 感染疾病
      • 胃腸道感染疾病
      • 院內感染
    • 腫瘤學
    • 傷口護理

第12章 噬菌體療法試劑盒市場（依最終用戶分類）

  • 生物製藥公司
  • 診斷中心
  • 醫院
  • 研究所
    • 學術機構
    • CRO（受託研究機構）
      • 臨床服務
      • 臨床前服務

第13章 噬菌體療法試劑盒市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 噬菌體療法試劑盒市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國噬菌體療法試劑盒市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章美國噬菌體療法試劑盒市場

第17章：中國噬菌體療法試劑盒市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Adaptive Phage Therapeutics, Inc.
  • Armata Pharmaceuticals, Inc.
  • BiomX, Inc.
  • ContraFect Corporation
  • Eliava BioPreparations LTD
  • Eligo Bioscience SAS
  • Fixed-Phage Limited
  • Intralytix, Inc.
  • iNtRON BIoTechnology, Inc.
  • Locus Biosciences, Inc.
  • Micreos BV
  • Microgen
  • Phagelux, Inc.
  • Pherecydes Pharma SAS
  • Technophage
Product Code: MRR-AE420CB15404

The Phage Therapy Kits Market was valued at USD 428.13 million in 2025 and is projected to grow to USD 520.92 million in 2026, with a CAGR of 21.73%, reaching USD 1,696.24 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 428.13 million
Estimated Year [2026] USD 520.92 million
Forecast Year [2032] USD 1,696.24 million
CAGR (%) 21.73%

An integrative introduction to phage therapy kits highlighting how standardized reagents and workflows are enabling translational science across research, clinical, and industrial domains

Phage therapy kits are converging with advances in microbiology, genomics, and clinical practice to create a rapidly maturing suite of tools that support discovery, diagnostics, and therapeutic application development. These kits bundle reagents, controls, and protocols to enable reproducible isolation, purification, quantification, and sequencing of bacteriophages across research laboratories, clinical settings, and industrial environments. As scientific and regulatory stakeholders seek alternatives to traditional antimicrobials, phage-based approaches have transitioned from academic curiosity to practical workflows that require standardized, high-quality kits for consistent results.

Moreover, the interplay between research-driven innovation and translational application has intensified demands on kit manufacturers to provide integrated solutions that address variability in sample matrices, sensitivity requirements, and downstream analytical platforms. Consequently, collaborators across biopharmaceutical R&D, diagnostic developers, and agricultural hygiene teams are increasingly reliant on kits that reduce technical barriers and accelerate experimental reproducibility. Transitioning from proof-of-concept to routine use, these kits are being adapted for therapeutic development pipelines, hospital infection control programs, food safety verification, and basic and commercial research workflows.

In this context, stakeholders must navigate evolving technical expectations, regulatory considerations, and operational deployment challenges. This executive summary synthesizes critical trends, regulatory headwinds, segmentation insights, and pragmatic recommendations to inform strategic planning for organizations engaging with phage therapy kits in research, clinical, and applied domains.

How rapid technical advances, expanding clinical interest, and cross-sector adoption are reshaping the phage therapy kits landscape into a more standardized and scalable ecosystem

The landscape for phage therapy kits is undergoing transformative shifts driven by technological maturation, heightened clinical interest, and cross-sector adoption. Advances in sequencing and high-throughput assays have increased the fidelity and speed of phage identification, while improved purification and quantification reagents have reduced variability between laboratories. As a result, kit vendors are innovating to deliver turnkey solutions that lower the barrier to entry for non-specialist labs and accelerate iterative cycles of R&D and product development.

Concurrently, clinical stakeholders are pushing for more standardized diagnostic and therapeutic workflows. This demand fuels development of kits tailored to clinical validation and regulatory submission paths, which in turn prompts suppliers to incorporate robust controls and traceable reagents. At the same time, agricultural and food safety actors are embracing phage-based tools for pathogen surveillance and contamination control, prompting diversification of kit portfolios to address varied sample types and regulatory regimes.

Transitioning from niche research tools to broadly deployable platforms, the ecosystem now emphasizes interoperability with common laboratory instruments, modular kit architectures, and digital support resources such as protocol repositories and data analysis pipelines. Taken together, these dynamics are fostering a more predictable and scalable environment for kit adoption, while also increasing competitive pressure on providers to demonstrate quality, reproducibility, and regulatory awareness.

Assessing the practical commercial implications of recent tariff measures that are reshaping procurement, supply chain strategies, and vendor selection for laboratory consumables and kits

Tariff policy changes implemented in 2025 have introduced new considerations for companies that manufacture, distribute, or procure phage therapy kits. Increased duties on certain laboratory consumables and reagents have raised landed costs for organizations that rely on cross-border supply chains, prompting procurement teams to reassess sourcing strategies and total landed expense. In response, many manufacturers and distributors are exploring nearshoring, dual-sourcing, and strategic inventory placement to mitigate exposure to tariff volatility and to preserve continuity of supply for critical components such as specialized buffers and control materials.

Additionally, tariffs have indirectly influenced supplier selection criteria by elevating the importance of localized regulatory compliance, lead-time reliability, and supplier transparency. As a consequence, purchasers are placing higher value on vendors that can demonstrate robust quality management systems, clear supply chain traceability, and regional distribution footprints that reduce customs complexity. Meanwhile, research laboratories and clinical centers are adapting purchasing workflows to account for extended procurement cycles and potential customs delays, and they are increasing engagement with vendors on forecasting and contractual assurances.

Ultimately, while tariffs have not altered the scientific rationale for phage approaches, they have become a material commercial factor. Companies that proactively redesign supply chains, diversify manufacturing locations, and provide clear logistics support will be better positioned to sustain customer relationships and operational resilience under shifting trade conditions.

Comprehensive segmentation insights revealing how application, kit type, end user, delivery method, and product type intersect to shape unmet needs and supplier differentiation

Understanding segmentation is critical when evaluating product positioning, R&D focus, and commercial outreach for phage therapy kits. Based on application, demand originates from agricultural contexts focused on pathogen control in crops and livestock, food safety programs seeking reliable pathogen detection and verification, research activities that span both basic research and commercial R&D, and therapeutic development pathways targeting infectious diseases, oncology applications, and wound healing interventions. Within the research segment, basic research prioritizes platform versatility and exploratory reagents, while commercial R and D emphasizes reproducibility and regulatory-grade documentation. Therapeutic applications fragment further into infectious disease workstreams such as gastrointestinal infections and hospital-acquired infections as well as specialized oncology and wound healing programs that integrate phage biology with adjunctive therapies.

Based on kit type, product portfolios include complete kits designed for end-to-end workflows, consumables intended for routine laboratory use, and reagent kits focused on specific assay components. Reagent offerings typically comprise controls, lysis buffers, and staining reagents, with controls themselves differentiated into negative and positive controls to support assay validation and quality assurance. Each kit type implies differing expectations for documentation, shelf life, and lot-to-lot consistency, which informs manufacturing and QA investments.

Based on end user, adoption patterns vary among biopharmaceutical companies that require GMP-aware inputs, diagnostic centers and hospitals that favor clinical-grade performance, and research laboratories including academic institutions and contract research organizations. Within contract research organizations, service lines split into clinical services and preclinical services, each demanding distinct product attributes and support infrastructures.

Based on delivery method, therapeutic and experimental applications use injection routes such as intramuscular, intravenous, and subcutaneous administration, as well as oral and topical formulations, which dictate formulation stability and sterility requirements. Finally, based on product type, instruments and consumables align to diagnostic kits, purification kits, quantification kits, and sequencing kits. Quantification tools often involve plaque assay kits and qPCR kits, with the latter subdividing into probe-based and SYBR Green chemistries, each imposing distinct assay design and validation needs. Integrating these segmentation lenses clarifies where unmet needs persist and where suppliers can differentiate through tailored product specifications, regulatory-grade documentation, and customer-centric service models.

Regional strategic dynamics and operational imperatives highlighting how Americas, Europe Middle East & Africa, and Asia-Pacific demand differentiated product, regulatory, and distribution approaches

Regional dynamics materially influence adoption pathways, regulatory expectations, and commercial strategies for phage therapy kits. In the Americas, robust biotech innovation hubs, extensive clinical trial activity, and a receptive regulatory environment for alternative antimicrobials create fertile conditions for both research-oriented and translational kit adoption. This region also demands scalable supply chains and strong post-market support to serve a mixture of academic, clinical, and commercial end users.

In Europe, Middle East & Africa, diversity across regulatory regimes and healthcare infrastructures necessitates flexible go-to-market approaches. Western European countries with established phage research traditions emphasize rigorous clinical validation, while emerging markets within the region may prioritize cost-effective solutions and simple operational footprints. Stakeholders in this region frequently require multilingual regulatory documentation and collaboration with local distributors to navigate heterogeneous market access pathways.

In the Asia-Pacific region, rapid growth in biotechnology research, sizable agricultural sectors, and expanding clinical research capacity drive demand across multiple kit categories. Manufacturers aiming to scale here must accommodate a wide array of laboratory instrument platforms, localized quality standards, and pricing expectations. Across all regions, local partnerships, regional manufacturing or distribution hubs, and proactive regulatory engagement improve market access and support long-term customer relationships. Recognizing these regional particularities enables suppliers to tailor product specifications, support offerings, and commercial models to match customer expectations and operational realities.

Key company-level insights on how product validation, quality systems, and strategic partnerships create competitive advantage and influence adoption among clinical and research buyers

The competitive environment for phage therapy kits features a mix of specialized reagent manufacturers, instrument incumbents expanding into phage-relevant workflows, and boutique providers offering niche, high-performance solutions. Leading suppliers differentiate through depth of technical validation, availability of clinical- or research-grade documentation, and the breadth of their product ecosystems that support upstream and downstream workflows. In addition, companies that invest in robust quality management systems, lot-level traceability, and clear instructions for use position themselves more favorably for adoption by diagnostic centers and biopharmaceutical developers.

Strategic partnerships between kit manufacturers and academic or clinical centers accelerate validation and build credibility, while collaborations with distribution networks enhance regional market penetration. Moreover, firms that provide value-added services such as assay optimization, protocol training, and data analysis support increase customer retention and reduce adoption friction. As procurement teams increasingly evaluate total cost of ownership and logistical reliability, vendors that can demonstrate predictable supply, scalable manufacturing, and responsive technical support enjoy a competitive advantage.

Finally, intellectual property around assay chemistries, control materials, and kit configurations remains a differentiating factor. Companies balancing proprietary innovations with open protocols can capture both high-margin specialty segments and broader-volume institutional accounts. Consequently, strategic choices about openness, partnership, and vertical integration will shape competitive positioning over the coming years.

Actionable recommendations for industry leaders to fortify validation, diversify supply chains, and enhance customer engagement to drive durable adoption of phage therapy kits

Industry leaders should prioritize actions that strengthen technical credibility, supply resilience, and customer engagement to capture opportunities within the phage kit ecosystem. First, invest in robust validation packages that include clinical- and research-grade documentation, lot-to-lot performance data, and third-party comparability studies. These materials reduce adoption friction for regulated end users and accelerate integration into translational workflows. Second, diversify manufacturing and distribution footprints to mitigate tariff exposure and customs-related delays, and develop contingency sourcing plans for critical reagents to sustain continuous supply.

Next, elevate post-sale value by offering protocol support, training resources, and optional assay optimization services. This approach not only improves outcomes for users but also fosters long-term relationships and recurring revenue. Furthermore, cultivate strategic collaborations with academic centers, clinical research organizations, and agricultural research partners to validate real-world performance and generate compelling use cases. Simultaneously, refine product portfolios to offer modular kit options that align with differing end-user needs, such as clinical validation, high-throughput research, or field-deployable food safety applications.

Finally, invest in clear regulatory navigation resources and regional market entry plans that account for local compliance expectations. Together, these actions will enhance product trust, reduce procurement barriers, and accelerate uptake across research, clinical, and applied sectors.

An explanation of the evidence-based research methodology combining stakeholder interviews, literature synthesis, and analytical frameworks to ensure actionable and validated insights

This report synthesizes primary and secondary research methodologies to ensure analytical rigor and relevance to practitioners. Primary research includes structured interviews with stakeholders across biopharmaceutical R&D, diagnostic laboratories, hospital procurement teams, academic research groups, and agricultural science units. These interviews focused on technical requirements, validation expectations, procurement behavior, and logistical constraints that influence kit selection and use. In addition, discussions with manufacturing and distribution specialists provided practical perspectives on supply chain resilience, quality assurance practices, and regulatory documentation needs.

Secondary research encompassed a systematic review of peer-reviewed literature, regulatory guidance documents, and industry technical standards relevant to bacteriophage handling, assay development, and therapeutic formulation. The analysis also examined publicly available clinical trial registries, patent filings, and methodological publications to triangulate trends in assay chemistries, sequencing approaches, and quantification strategies. Data synthesis prioritized evidence-based findings, with careful cross-referencing between primary insights and documented technical sources.

Analytical frameworks used in the study include segmentation mapping, supply chain risk assessment, product differentiation matrices, and regulatory readiness evaluation. Throughout the research process, quality control steps involved validation of interview transcripts, cross-validation of technical claims against authoritative references, and iterative review by subject-matter experts to ensure accuracy and practical relevance for decision-makers.

Concluding perspective on the evolving role of phage therapy kits and the strategic levers companies must employ to drive reliable adoption across research, clinical, and applied settings

In conclusion, phage therapy kits occupy a pivotal role as enabling technologies at the intersection of research innovation, clinical translation, and applied pathogen control. Advances in sequencing, purification, and quantification are lowering technical barriers and expanding the contexts in which phage tools can be reliably applied. At the same time, commercial realities such as tariff changes, supply chain complexity, and diverse regional regulatory expectations necessitate thoughtful strategic responses from manufacturers and purchasers alike.

Strategically, organizations that invest in rigorous validation, diversify supply chains, and provide high-touch customer support will reduce adoption friction and build durable market relationships. Meanwhile, segmentation-aware product strategies that align kit types, delivery methods, and end-user requirements will reveal white spaces for differentiation-particularly where clinical-grade documentation, modular workflows, and interoperability with existing lab instrumentation are prioritized. Looking ahead, the confluence of technical maturity and cross-sector demand suggests that phage therapy kits will become standard components of the toolbox for researchers, clinicians, and applied science professionals, provided that vendors continue to emphasize quality, transparency, and regional adaptability.

Ultimately, the path to broader adoption involves not just better products but clearer support structures, regulatory engagement, and logistics solutions that collectively lower operational risk and improve outcomes for end users across sectors.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Phage Therapy Kits Market, by Kit Type

  • 8.1. Complete Kits
  • 8.2. Consumables
  • 8.3. Reagent Kits
    • 8.3.1. Controls
      • 8.3.1.1. Negative Controls
      • 8.3.1.2. Positive Controls
    • 8.3.2. Lysis Buffers
    • 8.3.3. Staining Reagents

9. Phage Therapy Kits Market, by Delivery Method

  • 9.1. Injection
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
    • 9.1.3. Subcutaneous
  • 9.2. Oral
  • 9.3. Topical

10. Phage Therapy Kits Market, by Product Type

  • 10.1. Diagnostic Kits
  • 10.2. Purification Kits
  • 10.3. Quantification Kits
    • 10.3.1. Plaque Assay Kits
    • 10.3.2. qPCR Kits
      • 10.3.2.1. Probe Based Kits
      • 10.3.2.2. Sybr Green Kits
  • 10.4. Sequencing Kits

11. Phage Therapy Kits Market, by Application

  • 11.1. Agricultural
  • 11.2. Food Safety
  • 11.3. Research
    • 11.3.1. Basic Research
    • 11.3.2. Commercial R And D
  • 11.4. Therapeutic
    • 11.4.1. Infectious Diseases
      • 11.4.1.1. Gastrointestinal Infections
      • 11.4.1.2. Hospital Acquired Infections
    • 11.4.2. Oncology
    • 11.4.3. Wound Healing

12. Phage Therapy Kits Market, by End User

  • 12.1. Biopharmaceutical Companies
  • 12.2. Diagnostic Centers
  • 12.3. Hospitals
  • 12.4. Research Laboratories
    • 12.4.1. Academic Institutions
    • 12.4.2. Contract Research Organizations
      • 12.4.2.1. Clinical Services
      • 12.4.2.2. Preclinical Services

13. Phage Therapy Kits Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Phage Therapy Kits Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Phage Therapy Kits Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Phage Therapy Kits Market

17. China Phage Therapy Kits Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Adaptive Phage Therapeutics, Inc.
  • 18.6. Armata Pharmaceuticals, Inc.
  • 18.7. BiomX, Inc.
  • 18.8. ContraFect Corporation
  • 18.9. Eliava BioPreparations LTD
  • 18.10. Eligo Bioscience SAS
  • 18.11. Fixed-Phage Limited
  • 18.12. Intralytix, Inc.
  • 18.13. iNtRON Biotechnology, Inc.
  • 18.14. Locus Biosciences, Inc.
  • 18.15. Micreos BV
  • 18.16. Microgen
  • 18.17. Phagelux, Inc.
  • 18.18. Pherecydes Pharma SAS
  • 18.19. Technophage

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHAGE THERAPY KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHAGE THERAPY KITS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PHAGE THERAPY KITS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PHAGE THERAPY KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PHAGE THERAPY KITS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHAGE THERAPY KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY COMPLETE KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY COMPLETE KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY COMPLETE KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY NEGATIVE CONTROLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY NEGATIVE CONTROLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY NEGATIVE CONTROLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY POSITIVE CONTROLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY POSITIVE CONTROLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY POSITIVE CONTROLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY LYSIS BUFFERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY LYSIS BUFFERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY LYSIS BUFFERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY STAINING REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY STAINING REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY STAINING REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DIAGNOSTIC KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DIAGNOSTIC KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DIAGNOSTIC KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PURIFICATION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PURIFICATION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PURIFICATION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PLAQUE ASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PLAQUE ASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PLAQUE ASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PROBE BASED KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PROBE BASED KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PROBE BASED KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SYBR GREEN KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SYBR GREEN KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SYBR GREEN KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SEQUENCING KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SEQUENCING KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SEQUENCING KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY AGRICULTURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY AGRICULTURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY AGRICULTURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY FOOD SAFETY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY FOOD SAFETY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY FOOD SAFETY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY COMMERCIAL R AND D, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY COMMERCIAL R AND D, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY COMMERCIAL R AND D, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY HOSPITAL ACQUIRED INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY HOSPITAL ACQUIRED INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY HOSPITAL ACQUIRED INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY WOUND HEALING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 286. GCC PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. GCC PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. GCC PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 289. GCC PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 290. GCC PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 291. GCC PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 292. GCC PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. GCC PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 294. GCC PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 295. GCC PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. GCC PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 297. GCC PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 298. GCC PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 299. GCC PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. GCC PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 301. GCC PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS PHAGE